NSCLC therapies should target ‘unique, identifiable’ genomic alterations in tumors
Joshua Bauml, MD, assistant professor of medicine in the division of hematology/oncology at Perelman School of Medicine at University of Pennsylvania, discusses the role of genomics in the management of non-small cell lung cancer, which has ‘completely changed’ the landscape of NSCLC and the management of the disease.
Identification of abnormalities in CLL leads to improved treatments
Danielle M. Brander, MD, assistant professor of medicine at Duke University and member of Duke Cancer Institute, discusses recent advances in understanding the heterogeneity and abnormalities of chronic lymphocytic leukemia and how these developments have led to better treatments as well as new therapies that aim to prevent resistance.
‘Exciting’ trials hold promise for new urothelial cancer treatments
Petros Grivas, MD, PhD, clinical director of the genitourinary cancers program and associate professor in the department of medicine (division of oncology) at the University of Washington, stresses the importance of clinical trials in evaluating and developing new therapies for urothelial cancer, including targeted agents and PARP inhibitors.
Genomics affect ‘every level’ of NSCLC management
Edward S. Kim, MD, FACP, chair of the department of solid tumor oncology and investigational therapeutics at Levine Cancer Institute at Atrium Health, stresses the importance of testing genomic markers in all patients with non-small cell lung cancer.
Genomic mutations drive therapeutic decisions in AML
Alexander Edward Perl, MD, MS, associate professor of medicine at the Hospital of the University of Pennsylvania, stresses the importance of understanding the genetics of acute myeloid leukemia in risk-stratifying patients and choosing the most appropriate treatment.
Immune effector cells play critical role in head and neck cancer biology
Nabil F. Saba, MD, professor in the department of hematology and medical oncology at Winship Cancer Institute at Emory University, discusses the role of genomics in the discovery of multiple targetable pathways in head and neck cancer, which is “highly immunogenic,” and in understanding the immune microenvironment of the disease.
Thank you for participating in this module. Click below to download the certificate.